Photo credit: IceCure Medical Ltd.
December 9, 2022 — A poster presentation during the Radiological Society of North America Scientific Session and Annual Meeting (RSNA 2022) featured IceCure Medical Ltd. and its minimally-invasive cryoablation technology. Addressing Increasing interest among breast and interventional radiologists in performing breast tumor cryoablation, Kenneth Tomkovich, MD, presented "To Freeze or Not To Freeze? That is the Question: Cryoablation for the Treatment of Breast Cancer.” Tomkovich was a Co-Primary investigator for IceCure's ICE3 clinical trial, and is a Diagnostic and Interventional Radiologist with Princeton Radiology, CentraState Medical Center, and Penn Princeton Medical Center in Princeton, New Jersey. Tomkovich presented interim data from the ICE3 clinical trial at RSNA 2021 with his presentation titled "Primary Treatment of Low Risk Breast Cancers Using Image-Guided Cryoablation: A 6 Year Update of the ICE3 Trial."
ICE3 is the largest controlled, multicenter clinical trial ever performed in the U.S. for liquid nitrogen-based cryoablation of small, low-risk, early-stage malignant breast tumors. Interim analysis submitted as part of IceCure’s filing a De Novo classification request with the FDA for marketing authorization of ProSense with Breakthrough Indication for early-stage, low-risk breast cancer patients at high risk to surgery, shows to date, there have been six cases of ipsilateral breast tumor recurrence (IBTR) out of 194 patients, or 3.09%. Final ICE3 5-year follow-up data is expected in the first half of 2024.
The Company was recently assigned a CPT Category III Code from the Centers for Medicare & Medicaid Services (CMS) for the its ProSense breast cancer cryoablation procedures, which is priced for coverage by the CMS at approximately $3,400 for the facility fee alone.
IceCure Medical Ltd. develops and markets ProSense, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared to-date by the U.S. Food and Drug Administration and approved in Europe with the CE Mark.
For more information: icecure-medical.com
July 30, 2024 
